The overexpression of PD-L1 in cancers such as gastric carcinoma, hepatocellular carcinoma, renal-cell carcinoma, esophageal carcinoma, pancreatic cancer, ovarian cancer, and bladder cancers is associated with poor clinical outcomes, and the detection of its levels has important clinical significance 1. This evidence concerns the gene CD274 and urinary bladder cancer.